Skip to main content

Challenges in the Diagnosis and Treatment of Lyme Disease

Abstract

Purpose of Review

Since recognition in 1975, Lyme disease has become the most common vector-borne illness in North America and Europe. The clinical features are well-characterized and treatment is usually curative, but misperceptions about morbidity persist. The purpose of this review is to examine advances in the diagnosis and treatment of Lyme disease, as well as ongoing management challenges.

Recent Findings

It is useful to recognize that Lyme disease occurs in stages, with early- and late-stage disease. Clinical expression is in part determined by Borrelial variability. For example, some strains of Borrelia burgdorferi, the causative organism in North America, are particularly arthritogenic. Most patients with early Lyme disease can be cured with a single course of oral antibiotic therapy, in contrast to some patients with Lyme arthritis, a late-stage manifestation, who are more antibiotic refractory and require other treatment strategies.

Summary

Successful treatment of Lyme disease begins with successful diagnosis and with an understanding of the emergence, clinical features, and impact of Lyme disease over the past half century.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.

    Steere AC, Malawista SE, Snydman DR, Shope RE, Andiman WA, Ross MR, et al. Lyme arthritis: an epidemic of oligoarticular arthritis in children and adults in three Connecticut communities. Arthritis Rheum. 1977;20(1):7–17.

    CAS  PubMed  Google Scholar 

  2. 2.

    Asbrink E, Hovmark A, Olsson I. Clinical manifestations of acrodermatitis chronica atrophicans in 50 Swedish patients. Zentralbl Bakteriol Mikrobiol Hyg A. 1986;263(1–2):253–61.

    CAS  PubMed  Google Scholar 

  3. 3.

    Ogrinc K, Lusa L, Lotric-Furlan S, Bogovic P, Stupica D, Cerar T, et al. Course and outcome of early European Lyme neuroborreliosis (Bannwarth syndrome): clinical and laboratory findings. Clin Infect Dis. 2016;63(3):346–53.

    CAS  PubMed  Google Scholar 

  4. 4.

    Steere AC, Bartenhagen NH, Craft JE, Hutchinson GJ, Newman JH, Rahn DW, et al. The early clinical manifestations of Lyme disease. Ann Intern Med. 1983;99(1):76–82.

    CAS  PubMed  Google Scholar 

  5. 5.

    Burgdorfer W, Barbour AG, Hayes SF, Benach JL, Grunwaldt E, Davis JP. Lyme disease-a tick-borne spirochetosis? Science. 1982;216(4552):1317–9.

    CAS  PubMed  Google Scholar 

  6. 6.

    Benach JL, Bosler EM, Hanrahan JP, Coleman JL, Habicht GS, Bast TF, et al. Spirochetes isolated from the blood of two patients with Lyme disease. N Engl J Med. 1983;308(13):740–2.

    CAS  PubMed  Google Scholar 

  7. 7.

    Steere AC, Grodzicki RL, Kornblatt AN, Craft JE, Barbour AG, Burgdorfer W, et al. The spirochetal etiology of Lyme disease. N Engl J Med. 1983;308(13):733–40.

    CAS  PubMed  Google Scholar 

  8. 8.

    • Mead PS. Epidemiology of Lyme disease. Infect Dis Clin North Am. 2015;29(2):187–210. This review provides a comprehensive discussion of Lyme disease epidemiology.

    PubMed  Google Scholar 

  9. 9.

    Margos G, Vollmer SA, Ogden NH, Fish D. Population genetics, taxonomy, phylogeny and evolution of Borrelia burgdorferi sensu lato. Infect Genet Evol. 2011;11(7):1545–63.

    PubMed  PubMed Central  Google Scholar 

  10. 10.

    • Steere AC, Strle F, Wormser GP, Hu LT, Branda JA, Hovius JW, et al. Lyme borreliosis. Nat Rev Dis Primers. 2016;2:16090. This review is a thorough update by experts.

    PubMed  PubMed Central  Google Scholar 

  11. 11.

    Grillon A, Scherlinger M, Boyer PH, De Martino S, Perdriger A, Blasquez A, et al. Characteristics and clinical outcomes after treatment of a national cohort of PCR-positive Lyme arthritis. Semin Arthritis Rheum. 2019;48(6):1105–12.

    PubMed  Google Scholar 

  12. 12.

    Maraspin V, Mrvic T, Ruzic-Sabljic E, Jurcic V, Strle F. Acrodermatitis chronica atrophicans in children: report on two cases and review of the literature. Ticks Tick Borne Dis. 2019;10(1):180–5.

    PubMed  Google Scholar 

  13. 13.

    Bacon RM, Kugeler KJ, Mead PS. Surveillance for Lyme disease--United States, 1992–2006. Morbidity and mortality weekly report surveillance summaries (Washington, DC : 2002). 2008;57(10):1–9.

  14. 14.

    Eisen RJ, Eisen L, Beard CB. County-scale distribution of Ixodes scapularis and Ixodes pacificus (Acari: Ixodidae) in the continental United States. J Med Entomol. 2016;53(2):349–86.

    PubMed  PubMed Central  Google Scholar 

  15. 15.

    Centers for Disease Control. Data and surveillance Lyme disease 2019 [5/18/19]. Available from: https://www.cdc.gov/lyme/stats/index.html. Accessed 1 July 2019.

  16. 16.

    Reid MC, Schoen RT, Evans J, Rosenberg JC, Horwitz RI. The consequences of overdiagnosis and overtreatment of Lyme disease: an observational study. Ann Intern Med. 1998;128(5):354–62.

    CAS  PubMed  Google Scholar 

  17. 17.

    Schiffman EK, McLaughlin C, Ray JAE, Kemperman MM, Hinckley AF, Friedlander HG, et al. Underreporting of Lyme and other tick-borne diseases in residents of a high-incidence county, Minnesota, 2009. Zoonoses Public Health. 2018;65(2):230–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  18. 18.

    White J, Noonan-Toly C, Lukacik G, Thomas N, Hinckley A, Hook S, et al. Lyme disease surveillance in New York state: an assessment of case underreporting. Zoonoses Public Health. 2018;65(2):238–46.

    CAS  PubMed  Google Scholar 

  19. 19.

    Doyle TJ, Glynn MK, Groseclose SL. Completeness of notifiable infectious disease reporting in the United States: an analytical literature review. Am J Epidemiol. 2002;155(9):866–74.

    PubMed  Google Scholar 

  20. 20.

    Nelson CA, Saha S, Kugeler KJ, Delorey MJ, Shankar MB, Hinckley AF, et al. Incidence of clinician-diagnosed Lyme disease, United States, 2005-2010. Emerg Infect Dis. 2015;21(9):1625–31.

    CAS  PubMed  PubMed Central  Google Scholar 

  21. 21.

    Steere AC. Lyme disease. N Engl J Med. 1989;321(9):586–96.

    CAS  PubMed  Google Scholar 

  22. 22.

    Schoen RT. A case revealing the natural history of untreated Lyme disease. Nat Rev Rheumatol. 2011;7(3):179–84.

    CAS  PubMed  Google Scholar 

  23. 23.

    Smith RP, Schoen RT, Rahn DW, Sikand VK, Nowakowski J, Parenti DL, et al. Clinical characteristics and treatment outcome of early Lyme disease in patients with microbiologically confirmed erythema migrans. Ann Intern Med. 2002;136(6):421–8.

    PubMed  Google Scholar 

  24. 24.

    Matuschka FR, Ohlenbusch A, Eiffert H, Richter D, Spielman A. Antiquity of the Lyme-disease spirochaete in Europe. Lancet. 1995;346(8986):1367.

    CAS  PubMed  Google Scholar 

  25. 25.

    Keller A, Graefen A, Ball M, Matzas M, Boisguerin V, Maixner F, et al. New insights into the Tyrolean Iceman’s origin and phenotype as inferred by whole-genome sequencing. Nat Commun. 2012;3:698.

    PubMed  Google Scholar 

  26. 26.

    Poinar G. Spirochete-like cells in a Dominican amber Ambylomma tick (Arachnida: Ixodidae). Hist Biol. 2015;27(5):565–70.

    Google Scholar 

  27. 27.

    Spielman A. The emergence of Lyme disease and human babesiosis in a changing environment. Ann N Y Acad Sci. 1994;740:146–56.

    CAS  PubMed  Google Scholar 

  28. 28.

    Stanek G, Wormser GP, Gray J, Strle F. Lyme borreliosis. Lancet. 2012;379(9814):461–73.

    PubMed  Google Scholar 

  29. 29.

    Clow KM, Leighton PA, Ogden NH, Lindsay LR, Michel P, Pearl DL, et al. Northward range expansion of Ixodes scapularis evident over a short timescale in Ontario. Canada PLoS One. 2017;12(12):e0189393.

    PubMed  Google Scholar 

  30. 30.

    Gasmi S, Ogden NH, Lindsay LR, Burns S, Fleming S, Badcock J, et al. Surveillance for Lyme disease in Canada: 2009-2015. Canada communicable disease report =. Releve des maladies transmissibles au Canada. 2017;43(10):194–9.

    CAS  PubMed  Google Scholar 

  31. 31.

    Schwartz AM, Hinckley AF, Mead PS, Hook SA, Kugeler KJ. Surveillance for Lyme disease - United States, 2008–2015. Morbidity and mortality weekly report surveillance summaries (Washington, DC : 2002). 2017;66(22):1–12.

  32. 32.

    Rand PW, Lubelczyk C, Lavigne GR, Elias S, Holman MS, Lacombe EH, et al. Deer density and the abundance of Ixodes scapularis (Acari: Ixodidae). J Med Entomol. 2003;40(2):179–84.

    PubMed  Google Scholar 

  33. 33.

    Centers for Disease Control. Lyme disease—confirmed cases by month of disease onset, United States, 2001-2017 2018 [Available from: https://www.cdc.gov/lyme/stats/graphs.html.

  34. 34.

    Nigrovic LE, Neville DN, Balamuth F, Bennett JE, Levas MN, Garro AC. A minority of children diagnosed with Lyme disease recall a preceding tick bite. Ticks Tick Borne Dis. 2019;10(3):694–6.

    PubMed  Google Scholar 

  35. 35.

    Nadelman RB, Nowakowski J, Fish D, Falco RC, Freeman K, McKenna D, et al. Prophylaxis with single-dose doxycycline for the prevention of Lyme disease after an Ixodes scapularis tick bite. N Engl J Med. 2001;345(2):79–84.

    CAS  PubMed  Google Scholar 

  36. 36.

    Steere AC, Sikand VK. The presenting manifestations of Lyme disease and the outcomes of treatment. N Engl J Med. 2003;348(24):2472–4.

    PubMed  Google Scholar 

  37. 37.

    Wormser GP, Sudhindra P, Lopez E, Patel L, Rezai S, Brumbaugh AD, et al. Fatigue in patients with erythema migrans. Diagn Microbiol Infect Dis. 2016;86(3):322–6.

    PubMed  PubMed Central  Google Scholar 

  38. 38.

    Nadelman RB. Erythema migrans. Infect Dis Clin N Am. 2015;29(2):211–39.

    Google Scholar 

  39. 39.

    Steere AC. Lyme disease. N Engl J Med. 2001;345(2):115–25.

    CAS  PubMed  Google Scholar 

  40. 40.

    Waddell LA, Greig J, Lindsay LR, Hinckley AF, Ogden NH. A systematic review on the impact of gestational Lyme disease in humans on the fetus and newborn. PLoS One. 2018;13(11):e0207067.

    PubMed  PubMed Central  Google Scholar 

  41. 41.

    Robinson ML, Kobayashi T, Higgins Y, Calkins H, Melia MT. Lyme carditis. Infect Dis Clin N Am. 2015;29(2):255–68.

    Google Scholar 

  42. 42.

    • Three sudden cardiac deaths associated with Lyme carditis - United States, November 2012–July 2013. MMWR morbidity and mortality weekly report. 2013;62(49):993–6. A report of 3 deaths attibutable to Lyme disease.

  43. 43.

    Stanek G, Klein J, Bittner R, Glogar D. Isolation of Borrelia burgdorferi from the myocardium of a patient with longstanding cardiomyopathy. N Engl J Med. 1990;322(4):249–52.

    CAS  PubMed  Google Scholar 

  44. 44.

    N’Guyen Y, Lesaffre F, Metz D, de Martino S, Jaulhac B, Andreoletti L. No serological evidence for Borrelia burgdorferi sensu lato infection in patients with dilated cardiomyopathy in Northern France. Infectious diseases (London, England). 2016;48(10):763–4.

  45. 45.

    Pachner AR. CNS Lyme disease. Neurology. 1992;42(9):1849–50.

    CAS  PubMed  Google Scholar 

  46. 46.

    Clark JR, Carlson RD, Sasaki CT, Pachner AR, Steere AC. Facial paralysis in Lyme disease. Laryngoscope. 1985;95(11):1341–5.

    CAS  PubMed  Google Scholar 

  47. 47.

    Wong K, Sequeira S, Bechtel K. Pediatric bilateral facial paralysis: an unusual presentation of Lyme disease. Pediatric emergency care. 2018.

  48. 48.

    Gaudin RA, Jowett N, Banks CA, Knox CJ, Hadlock TA. Bilateral facial paralysis: a 13-year experience. Plast Reconstr Surg. 2016;138(4):879–87.

    CAS  PubMed  Google Scholar 

  49. 49.

    Tseng YJ, DeMaria A, Jr., Goldmann DA, Mandl KD. Claims-based diagnostic patterns of patients evaluated for Lyme disease and given extended antibiotic therapy. Vector borne and zoonotic diseases (Larchmont, NY). 2017;17(2):116–22.

    PubMed  Google Scholar 

  50. 50.

    Marques AR. Lyme neuroborreliosis. Continuum (Minneap Minn). 2015;21(6 Neuroinfectious Disease):1729–44.

    Google Scholar 

  51. 51.

    Halperin JJ. Lyme neuroborreliosis. Curr Opin Infect Dis. 2019;32(3):259–64.

    PubMed  Google Scholar 

  52. 52.

    Halperin JJ. Neuroborreliosis. Neurol Clin. 2018;36(4):821–30.

    PubMed  Google Scholar 

  53. 53.

    Patel K, Shah S, Subedi D. Clinical association: Lyme disease and Guillain-Barre syndrome. The American Journal of Emergency Medicine. 2017;35(10):1583.e1–2.

    Google Scholar 

  54. 54.

    Monteventi O, Steinlin M, Regenyi M, Roulet-Perez E, Weber P, Fluss J. Pediatric stroke related to Lyme neuroborreliosis: data from the Swiss NeuroPaediatric Stroke Registry and literature review. Eur J Paediatr Neurol. 2018;22(1):113–21.

    CAS  PubMed  Google Scholar 

  55. 55.

    Visser AE, Verduyn Lunel FM, Veldink JH, van den Berg LH. No association between Borrelia burgdorferi antibodies and amyotrophic lateral sclerosis in a case-control study. Eur J Neurol. 2017;24(1):227–30.

    CAS  PubMed  Google Scholar 

  56. 56.

    Logigian EL, Kaplan RF, Steere AC. Chronic neurologic manifestations of Lyme disease. N Engl J Med. 1990;323(21):1438–44.

    CAS  PubMed  Google Scholar 

  57. 57.

    Steere AC, Schoen RT, Taylor E. The clinical evolution of Lyme arthritis. Ann Intern Med. 1987;107(5):725–31.

    CAS  PubMed  Google Scholar 

  58. 58.

    Schoen R. Musculoskeletal manifestations of Lyme disease. Waltham, MA2009-Present.

  59. 59.

    Li X, McHugh GA, Damle N, Sikand VK, Glickstein L, Steere AC. Burden and viability of Borrelia burgdorferi in skin and joints of patients with erythema migrans or Lyme arthritis. Arthritis Rheum. 2011;63(8):2238–47.

    PubMed  PubMed Central  Google Scholar 

  60. 60.

    Steere AC, Angelis SM. Therapy for Lyme arthritis: strategies for the treatment of antibiotic-refractory arthritis. Arthritis Rheum. 2006;54(10):3079–86.

    CAS  PubMed  Google Scholar 

  61. 61.

    • Arvikar SL, Steere AC. Diagnosis and treatment of Lyme arthritis. Infect Dis Clin North Am. 2015;29(2):269–80. A review of the patterns of Lyme arthritis.

    PubMed  PubMed Central  Google Scholar 

  62. 62.

    Jones KL, McHugh GA, Glickstein LJ, Steere AC. Analysis of Borrelia burgdorferi genotypes in patients with Lyme arthritis: high frequency of ribosomal RNA intergenic spacer type 1 strains in antibiotic-refractory arthritis. Arthritis Rheum. 2009;60(7):2174–82.

    CAS  PubMed  PubMed Central  Google Scholar 

  63. 63.

    Steere AC, Klitz W, Drouin EE, Falk BA, Kwok WW, Nepom GT, et al. Antibiotic-refractory Lyme arthritis is associated with HLA-DR molecules that bind a Borrelia burgdorferi peptide. J Exp Med. 2006;203(4):961–71.

    CAS  PubMed  PubMed Central  Google Scholar 

  64. 64.

    Borchers AT, Keen CL, Huntley AC, Gershwin ME. Lyme disease: a rigorous review of diagnostic criteria and treatment. J Autoimmun. 2015;57:82–115.

    PubMed  Google Scholar 

  65. 65.

    •• Lochhead RB, Strle K, Kim ND, Kohler MJ, Arvikar SL, Aversa JM, et al. MicroRNA expression shows inflammatory dysregulation and tumor-like proliferative responses in joints of patients with postinfectious Lyme arthritis. Arthritis Rheumatol (Hoboken, NJ). 2017;69(5):1100–10. MicroRNA expression in Lyme arthritis synovium changes with disease persistence.

    CAS  Google Scholar 

  66. 66.

    Arvikar SL, Crowley JT, Sulka KB, Steere AC. Autoimmune arthritides, rheumatoid arthritis, psoriatic arthritis, or peripheral spondyloarthritis following Lyme disease. Arthritis Rheumatol (Hoboken, NJ). 2017;69(1):194–202.

    CAS  Google Scholar 

  67. 67.

    Wormser GP, McKenna D, Carlin J, Nadelman RB, Cavaliere LF, Holmgren D, et al. Brief communication: hematogenous dissemination in early Lyme disease. Ann Intern Med. 2005;142(9):751–5.

    PubMed  Google Scholar 

  68. 68.

    Wormser GP, Shapiro ED, Strle F. Studies that report unexpected positive blood cultures for Lyme borrelia - are they valid? Diagn Microbiol Infect Dis. 2017;89(3):178–81.

    PubMed  PubMed Central  Google Scholar 

  69. 69.

    Branda JA, Body BA, Boyle J, Branson BM, Dattwyler RJ, Fikrig E, et al. Advances in serodiagnostic testing for Lyme disease are at hand. Clin Infect Dis. 2018;66(7):1133–9.

    CAS  PubMed  Google Scholar 

  70. 70.

    Theel ES. The past, present, and (possible) future of serologic testing for Lyme disease. J Clin Microbiol. 2016;54(5):1191–6.

    CAS  PubMed  PubMed Central  Google Scholar 

  71. 71.

    Alby K, Capraro GA. Alternatives to serologic testing for diagnosis of Lyme disease. Clin Lab Med. 2015;35(4):815–25.

    PubMed  Google Scholar 

  72. 72.

    Alasel M, Keusgen M. Promising alternatives for one-tier testing of Lyme borreliosis. Clinica chimica acta; international journal of clinical chemistry. 2018;479:148–54.

    CAS  PubMed  Google Scholar 

  73. 73.

    Recommendations for test performance and interpretation from the Second National Conference on Serologic Diagnosis of Lyme Disease. MMWR Morbidity and mortality weekly report. 1995;44(31):590–1.

  74. 74.

    Marques AR. Laboratory diagnosis of Lyme disease: advances and challenges. Infect Dis Clin N Am. 2015;29(2):295–307.

    Google Scholar 

  75. 75.

    Moore A, Nelson C, Molins C, Mead P, Schriefer M. Current guidelines, common clinical pitfalls, and future directions for laboratory diagnosis of Lyme disease, United States. Emerg Infect Dis. 2016;22(7).

  76. 76.

    Nigrovic LE, Lipsett SC, Molins CR, Wormser GP, Bennett JE, Garro AC, et al. Higher C6 enzyme immunoassay index values correlate with a diagnosis of noncutaneous Lyme disease. Diagn Microbiol Infect Dis. 2019;94(2):160–4.

    CAS  PubMed  Google Scholar 

  77. 77.

    Rebman AW, Crowder LA, Kirkpatrick A, Aucott JN. Characteristics of seroconversion and implications for diagnosis of post-treatment Lyme disease syndrome: acute and convalescent serology among a prospective cohort of early Lyme disease patients. Clin Rheumatol. 2015;34(3):585–9.

    PubMed  Google Scholar 

  78. 78.

    Markowicz M, Kivaranovic D, Stanek G. Testing patients with non-specific symptoms for antibodies against Borrelia burgdorferi sensu lato does not provide useful clinical information about their aetiology. Clin Microbiol Infect. 2015;21(12):1098–103.

    CAS  PubMed  Google Scholar 

  79. 79.

    Lee-Lewandrowski E, Chen Z, Branda J, Baron J, Kaufman HW. Laboratory blood-based testing for Lyme disease at a national reference laboratory. Am J Clin Pathol. 2019;152(1):91–6.

    PubMed  Google Scholar 

  80. 80.

    Leeflang MM, Ang CW, Berkhout J, Bijlmer HA, Van Bortel W, Brandenburg AH, et al. The diagnostic accuracy of serological tests for Lyme borreliosis in Europe: a systematic review and meta-analysis. BMC Infect Dis. 2016;16:140.

    CAS  PubMed  PubMed Central  Google Scholar 

  81. 81.

    Lantos PM, Branda JA, Boggan JC, Chudgar SM, Wilson EA, Ruffin F, et al. Poor positive predictive value of Lyme disease serologic testing in an area of low disease incidence. Clin Infect Dis. 2015;61(9):1374–80.

    PubMed  PubMed Central  Google Scholar 

  82. 82.

    Connally NP, Hinckley AF, Feldman KA, Kemperman M, Neitzel D, Wee SB, et al. Testing practices and volume of non-Lyme tickborne diseases in the United States. Ticks Tick Borne Dis. 2016;7(1):193–8.

    PubMed  Google Scholar 

  83. 83.

    Webber BJ, Burganowski RP, Colton L, Escobar JD, Pathak SR, Gambino-Shirley KJ. Lyme disease overdiagnosis in a large healthcare system: a population-based, retrospective study. Clin Microbiol Infect. 2019.

  84. 84.

    Treatment of Lyme disease. Jama. 2016;315(22):2461–2.

  85. 85.

    • Sanchez E, Vannier E, Wormser GP, Hu LT. Diagnosis, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: a review. JAMA. 2016;315(16):1767–77. A review focusing on Lyme disease treatment.

    CAS  PubMed  Google Scholar 

  86. 86.

    Strle F, Stupica D, Bogovic P, Visintainer P, Wormser GP. Is the risk of early neurologic Lyme borreliosis reduced by preferentially treating patients with erythema migrans with doxycycline? Diagn Microbiol Infect Dis. 2018;91(2):156–60.

    CAS  PubMed  Google Scholar 

  87. 87.

    Cadavid D, Auwaerter PG, Rumbaugh J, Gelderblom H. Antibiotics for the neurological complications of Lyme disease. The Cochrane database of systematic reviews. 2016;12:Cd006978.

  88. 88.

    Dersch R, Freitag MH, Schmidt S, Sommer H, Rauer S, Meerpohl JJ. Efficacy and safety of pharmacological treatments for acute Lyme neuroborreliosis - a systematic review. Eur J Neurol. 2015;22(9):1249–59.

    CAS  PubMed  Google Scholar 

  89. 89.

    Jowett N, Gaudin RA, Banks CA, Hadlock TA. Steroid use in Lyme disease-associated facial palsy is associated with worse long-term outcomes. Laryngoscope. 2017;127(6):1451–8.

    CAS  PubMed  Google Scholar 

  90. 90.

    Wormser GP, McKenna D, Scavarda C, Karmen C. Outcome of facial palsy from Lyme disease in prospectively followed patients who had received corticosteroids. Diagn Microbiol Infect Dis. 2018;91(4):336–8.

    CAS  PubMed  Google Scholar 

  91. 91.

    Lantos PM. Chronic Lyme disease. Infect Dis Clin N Am. 2015;29(2):325–40.

    Google Scholar 

  92. 92.

    Aguero-Rosenfeld ME, Wormser GP. Lyme disease: diagnostic issues and controversies. Expert Rev Mol Diagn. 2015;15(1):1–4.

    CAS  PubMed  Google Scholar 

  93. 93.

    Dersch R, Sarnes AA, Maul M, Hottenrott T, Baumgartner A, Rauer S, et al. Quality of life, fatigue, depression and cognitive impairment in Lyme neuroborreliosis. J Neurol. 2015;262(11):2572–7.

    PubMed  Google Scholar 

  94. 94.

    Weitzner E, McKenna D, Nowakowski J, Scavarda C, Dornbush R, Bittker S, et al. Long-term assessment of post-treatment symptoms in patients with culture-confirmed early Lyme disease. Clin Infect Dis. 2015;61(12):1800–6.

    PubMed  PubMed Central  Google Scholar 

  95. 95.

    Wills AB, Spaulding AB, Adjemian J, Prevots DR, Turk SP, Williams C, et al. Long-term follow-up of patients with Lyme disease: longitudinal analysis of clinical and quality-of-life measures. Clin Infect Dis. 2016;62(12):1546–51.

    PubMed  PubMed Central  Google Scholar 

  96. 96.

    Berende A, Nieuwenhuis L, Ter Hofstede HJM, Vos FJ, Vogelaar ML, Tromp M, et al. Cost-effectiveness of longer-term versus shorter-term provision of antibiotics in patients with persistent symptoms attributed to Lyme disease. PLoS One. 2018;13(4):e0195260.

    PubMed  PubMed Central  Google Scholar 

  97. 97.

    • Berende A, ter Hofstede HJ, Vos FJ, van Middendorp H, Vogelaar ML, Tromp M, et al. Randomized trial of longer-term therapy for symptoms attributed to Lyme disease. N Engl J Med. 2016;374(13):1209–20. A study demonstrating lack of benefit for long-term antibiotic therapy.

    CAS  PubMed  Google Scholar 

  98. 98.

    Aucott JN. Posttreatment Lyme disease syndrome. Infect Dis Clin N Am. 2015;29(2):309–23.

    Google Scholar 

  99. 99.

    Rebman AW, Bechtold KT, Yang T, Mihm EA, Soloski MJ, Novak CB, et al. The clinical, symptom, and quality-of-life characterization of a well-defined group of patients with posttreatment Lyme disease syndrome. Front Med. 2017;4:224.

    Google Scholar 

  100. 100.

    Wormser GP, Weitzner E, McKenna D, Nadelman RB, Scavarda C, Nowakowski J. Long-term assessment of fatigue in patients with culture-confirmed Lyme disease. Am J Med. 2015;128(2):181–4.

    PubMed  Google Scholar 

  101. 101.

    Wormser GP, Weitzner E, McKenna D, Nadelman RB, Scavarda C, Molla I, et al. Long-term assessment of health-related quality of life in patients with culture-confirmed early Lyme disease. Clin Infect Dis. 2015;61(2):244–7.

    PubMed  Google Scholar 

  102. 102.

    Adrion ER, Aucott J, Lemke KW, Weiner JP. Health care costs, utilization and patterns of care following Lyme disease. PLoS One. 2015;10(2):e0116767.

    PubMed  PubMed Central  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Robert T. Schoen.

Ethics declarations

Conflict of Interest

Dr. Schoen has no conflicts of interest to disclose.

Human and Animal Rights and Informed Consent

All reported studies/experiments with human or animal subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki declaration and its amendments, institutional/national research committee standards, and international/national/ institutional guidelines).

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Infection and Arthritis

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Schoen, R.T. Challenges in the Diagnosis and Treatment of Lyme Disease. Curr Rheumatol Rep 22, 3 (2020). https://doi.org/10.1007/s11926-019-0857-2

Download citation

Keywords

  • Lyme disease
  • Lyme arthritis
  • Lyme disease treatment